INCB047986 in Rheumatoid Arthritis
A Double-Blind, Placebo-Controlled Study Exploring the Safety, Tolerability, and Efficacy of a 28-Day Course of INCB047986 in Subjects With Active Rheumatoid Arthritis
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
California
-
Orange, California, United States
-
-
Florida
-
Debary, Florida, United States
-
Palm Harbor, Florida, United States
-
Tampa, Florida, United States
-
-
Maryland
-
Frederick, Maryland, United States
-
-
North Carolina
-
Charlotte, North Carolina, United States
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States
-
-
Texas
-
Austin, Texas, United States
-
The Woodlands, Texas, United States
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Men or women aged 18 to 75 years, inclusive.
- Body mass index between 18 and 40 kg/m^2, inclusive.
- Subjects must have a diagnosis of rheumatoid arthritis (RA) of at least 6 months' duration at the time of screening and must satisfy the ACR/European League Against Rheumatism (EULAR) 2010 Classification Criteria (Appendix B).
Subjects must have active moderate to severe RA as determined by the following:
- ≥ 6 tender joints (28 joint count),
- ≥ 4 swollen joints (28 joint count), and
- CRP level ≥ 6 mg/L.
- Subjects must have a negative tuberculosis (TB) test (QuantiFERON®-TB Gold test or purified protein derivative (PPD)) at screening.
Exclusion Criteria:
- Current or recent history of severe and/or progressive uncontrolled renal, hepatic, hematologic, gastrointestinal, pulmonary, cardiac, neurological, or cerebral disease.
- Current or recent history (< 30 days before screening and/or < 45 days before randomization) of a clinically meaningful bacterial, fungal, parasitic, or mycobacterial infection.
- Onset of RA before the age of 16 years.
- History of known or currently suspected inflammatory disease other than RA
- Current regimen of prednisone or equivalent with an average daily dose of > 10 mg or having been treated with a stable daily dose ≤ 10 mg for < 6 weeks.
- Previous treatment with at Janus kinase (JAK) inhibitor.
- Significant impairment of bone marrow function present at screening
- Receipt of any live vaccine within 2 months before screening or anticipated need for a live vaccine within the 2 months after last dose of study drug.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: INCB047986 4 mg QD
INCB047986 4 mg will be orally self-administered once daily (QD) for 28 days.
|
|
|
Experimental: INCB047986 8 mg QD
INCB047986 8 mg will be orally self-administered once daily (QD) for 28 days.
|
|
|
Experimental: INCB047986 12 mg QD
INCB047986 12 mg will be orally self-administered once daily (QD) for 28 days.
|
|
|
Experimental: INCB047986 placebo QD
INCB047986 placebo will be orally self-administered once daily (QD) for 28 days.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Percentage of participants with adverse events, changes in electrocardiograms (ECGs), vital signs, physical examinations, or clinical laboratory evaluations
Time Frame: Baseline through day 28
|
Baseline through day 28
|
|
Percentage of Participants Achieving American College of Rheumatology, 20% Improvement (ACR20)
Time Frame: Baseline through Day 28
|
Baseline through Day 28
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Percentage of subjects achieving ACR20 at each visit assessed.
Time Frame: Baseline, Day 8, 15 and Follow-Up
|
Baseline, Day 8, 15 and Follow-Up
|
|
Percentage of subjects achieving American College of Rheumatology, 50% improvement (ACR50) at each visit assessed.
Time Frame: Baseline, Day 8, 15 28 and Follow-Up
|
Baseline, Day 8, 15 28 and Follow-Up
|
|
Percentage of subjects achieving American College of Rheumatology, 70% improvement (ACR70) at each visit assessed.
Time Frame: Baseline, Day 8, 15 28 and Follow-Up
|
Baseline, Day 8, 15 28 and Follow-Up
|
|
Change in Disease Activity Score - 28-joint count (DAS28) C-reactive protein (CRP) at the Day 28 visit.
Time Frame: Day 28
|
Day 28
|
|
Change in DAS28 erythrocyte sedimentation rate (ESR) at the Day 28 visit.
Time Frame: Day 28
|
Day 28
|
|
Percentage of subjects achieving a DAS28 of ≤ 3.2 at the Day 28 visit.
Time Frame: Day 28
|
Day 28
|
|
Percentage of subjects achieving a DAS28 of ≤ 2.6 at the Day 28 visit.
Time Frame: Day 28
|
Day 28
|
|
Change in individual American College of Rheumatology (ACR) assessments.
Time Frame: Day 28
|
Day 28
|
|
Preliminary pharmacokinetic (PK)
Time Frame: Evaluated after 15 days of treatment
|
Evaluated after 15 days of treatment
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Richard Levy, MD, Incyte Corporation
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- INCB 47986-202
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.